Remove Animal Testing Remove Laboratories Remove Packaging
article thumbnail

Article Periodic Thank You Commission unveils “one substance, one assessment” reform package

Agency IQ

Commission unveils “one substance, one assessment” reform package The Commission has long aspired to realize its one substance, one assessment concept in the EU’s chemical regulatory regime. This also has clear potential to reduce animal testing, another key commitment made by the Commission.

article thumbnail

Rapid delivery of toxicological material

Drug Target Review

Rapid delivery of IND-enabling Tox testing is crucial for a timely IND submission Advanced technologies enabling increasingly rapid timelines from vector construction to good manufacturing practice (GMP) manufacture brings the prospect of ever shorter timelines to IND readiness. FDA no longer has to require animal testing for new drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article Periodic Thank You European Commission issues EU-wide rules on pesticide ingredients

Agency IQ

Like the registration requirement under REACH, this provision has been added to support data sharing for the same substances, to help limit potential data gaps among individual companies and, in turn, decrease the need for resorting to animal testing.

article thumbnail

Article EMA Thank You New guidance provides definition for orphan device, offers alternative trial designs

Agency IQ

Other work packages for the ODTF include information about clinical evidence for this device type, conditional certification, and the use of registries to support conformity assessment. Some of these are laboratory and animal tests, cadaveric studies and data from similar devices.

Trials 40
article thumbnail

A therapy candidate for fatal prion diseases turns off disease-causing gene

Broad Institute

The first problem they had to tackle was the editor’s size, because the editor needs to be small enough to be packaged and delivered to specific cells in the body. However, with a strong therapy design and promising laboratory results in hand, the researchers have good reason to be hopeful.

Disease 142
article thumbnail

Levers for Biological Progress

Codon

” Nobody really knows without trying it out in the laboratory. Though my focus in this essay is narrow — I don’t discuss bottlenecks in clinical trials, human disease, or animal testing — I hope others will take on these challenges in similar essays. Subscribe to Asimov Press. There are a few reasons.

DNA 130
article thumbnail

Analysis Life Sciences Thank You Congress’ asks for FDA in the budget bill: Diagnostics, drug importation, vouchers and EtO updates

Agency IQ

BY LAURA DIANGELO, MPH | MAR 6, 2024 5:54 PM CST Fiscal year 2024 appropriations bills On March 3, 2024, House and Senate appropriators released a package of final fiscal year (FY) 2024 appropriations bills. AgencyIQ has the highlights. As POLITICO reported , this generally represents a 5.2% This is already raising some red flags.

FDA 40